$1.08
0.92% today
Nasdaq, Nov 06, 10:14 pm CET
ISIN
US3741631036
Symbol
GERN

Geron Corporation Stock price

$1.09
-0.19 14.84% 1M
-0.33 23.24% 6M
-2.45 69.21% YTD
-3.13 74.17% 1Y
-1.01 48.10% 3Y
-0.74 40.44% 5Y
-2.52 69.81% 10Y
-7.50 87.32% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
-0.06 5.22%
ISIN
US3741631036
Symbol
GERN
Industry

Key metrics

Basic
Market capitalization
$695.4m
Enterprise Value
$426.5m
Net debt
positive
Cash
$388.0m
Shares outstanding
637.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.2 | 3.3
EV/Sales
2.6 | 2.0
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
47.2%
Return on Equity
-62.3%
ROCE
-16.1%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$164.5m | $211.9m
EBITDA
$-78.0m | $-81.0m
EBIT
$-79.1m | $-65.7m
Net Income
$-88.0m | $-74.1m
Free Cash Flow
$-178.3m
Growth (TTM | estimate)
Revenue
11,903.7% | 175.2%
EBITDA
65.6% | 53.0%
EBIT
65.2% | 62.2%
Net Income
59.9% | 57.6%
Free Cash Flow
14.5%
Margin (TTM | estimate)
Gross
97.8%
EBITDA
-47.4% | -38.3%
EBIT
-48.1%
Net
-53.5% | -35.0%
Free Cash Flow
-108.4%
More
EPS
$-0.1
FCF per Share
$-0.3
Short interest
14.2%
Employees
229
Rev per Employee
$340.0k
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

11x Buy
73%
3x Hold
20%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

Buy
73%
Hold
20%
Sell
7%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
164 164
11,904% 11,904%
100%
- Direct Costs 3.64 3.64
18,100% 18,100%
2%
161 161
18,384% 18,384%
98%
- Selling and Administrative Expenses 158 158
49% 49%
96%
- Research and Development Expense 80 80
34% 34%
49%
-78 -78
66% 66%
-47%
- Depreciation and Amortization 1.13 1.13
22% 22%
1%
EBIT (Operating Income) EBIT -79 -79
65% 65%
-48%
Net Profit -88 -88
60% 60%
-54%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
Seeking Alpha
one day ago
Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Eid - Executive VP of Research & Development and Chief Medical Officer Michelle Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Offic...
Neutral
Business Wire
one day ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the pot...
Neutral
Business Wire
2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in ...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today